CStone out-licenses sugemalimab rights in MENA region

22 November 2024

Chinese biopharma CStone Pharmaceuticals (HKEX: 2616) has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE).

Under the license and commercialization agreement, Pharmalink will gain the commercial rights for sugemalimab in the Middle East and North Africa (MENA) Region, including Saudi Arabia, UAE, Kuwait, Qatar, Oman, Bahrain, Algeria, Tunisia, Egypt, Morocco and Libya, and South Africa.

In return, CStone will receive undisclosed upfront, regulatory milestone payments and royalties on net sales of sugemalimab from Pharmalink, while Pharmalink will be responsible for the regulatory activities and commercialization of sugemalimab in the abovementioned regions. CStone will be responsible for the supply of sugemalimab.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK